10x Genomics Stock News

These seven of the best stocks to buy in June. TXG, BRKR, ETSY, PODD, MAR, RH and SEDG can make excellent investments.

Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.

Here's why three Fool.com contributors love 10x Genomics, Axsome Therapeutics, and Doximity.

10x Genomics (TXG) delivered earnings and revenue surprises of -2.70% and 1.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics, Inc. (NASDAQ:TXG ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Cassie Corneau - Investor Relations and Strategic Finance Serge Saxonov - Chief Executive

This biotech's products are a must-have for scientists.

The growth selloff continues to persist and with the Ukraine war raging, persistent inflation and rate hikes on the horizon, it makes sense that high multiple growth is largely out of favor.

During the last session, 10x Genomics Inc. (NASDAQ:TXG)’s traded shares were 0.71 million. At the end of the trading day, the stock’s price was $61.67, reflecting an intraday loss of -8.16% or -$5.48. The 52-week high for the TXG share is $208.99, that puts it down -238.88 from that peak though still a striking -5.64% … 10x Genomics Inc. (NASDAQ: TXG) Stock Dropped -35.83% Over A Month – Is There Any Hope Of A Gain? Read More »

PLEASANTON, Calif., March 1, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming Cowen 42nd Annual Health Care Conference. 10x Genomics''…

10X Genomics (TXG) was added as a new short idea at Hedgeye, which sees a deceleration in NIH funding in terms of new funded scientists, a key input for Hedgeye''s revenue…

10x Genomics <> reached a new 52-week low on Thursday as analysts trimmed their price targets on the stock in reaction to the company’s Q4 2021 earnings release

Investors were disappointed with the company''s 2022 guidance.

Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. 10x Genomics (TXG) -16%. iSpecimen ISPC -10%.

The stock fell by nearly 25% as markets reacted to the lab tools firm''s 2022 revenue outlook.

Investors were disappointed with the company's 2022 guidance.